Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL
Prof Brian Hill - Cleveland Clinic, Cleveland, USA
Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL ( Prof Brian Hill - Cleveland Clinic, Cleveland, USA )
11 Dec 2021
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma
Prof Elizabeth Budde - City of Hope, Duarte, USA
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma ( Prof Elizabeth Budde - City of Hope, Duarte, USA )
11 Dec 2021
Study indicates circulating tumour cell assessment should be part of multiple my...
Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain
Study indicates circulating tumour cell assessment should be part of multiple myeloma diagnostic workup ( Dr Juan-José Garcés - Clinica Universidad de Navarra, Pamplona, Spain )
11 Dec 2021
Initial treatment options for relapsed/refractory multiple myeloma patients
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
Initial treatment options for relapsed/refractory multiple myeloma patients ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
11 Dec 2021
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iN...
Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston...
ZUMA-5 update: Axicabtagene ciloleucel continues to show strong effect in R/R iNHL ( Prof Sattva Neelapu - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Dec 2021
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LB...
Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, U...
Lisocabtagene maraleucel demonstrates improvement over standard of care in 2L LBCL ( Dr Manali Kamdar - The University of Colorado Anschutz Medical Campus, Aurora, USA )
11 Dec 2021
Post-HSCT management of ALL - Adult ALL perspective
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Post-HSCT management of ALL - Adult ALL perspective ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
6 Dec 2021
Safety profile of BiTE therapy
Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany
Safety profile of BiTE therapy ( Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany )
2 Dec 2021
Treating late relapse of paediatric ALL
Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany
Treating late relapse of paediatric ALL ( Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany )
2 Dec 2021
Anti-CD38 immunotherapy treatment for multiple myeloma
Prof Xavier Leleu - CHU de Poitiers, Poitiers, France
Anti-CD38 immunotherapy treatment for multiple myeloma ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )
22 Nov 2021
Paediatric ALL perspective
Prof Andrea Biondi - University of Milano-Bicocca, Milan, Italy
Paediatric ALL perspective ( Prof Andrea Biondi - University of Milano-Bicocca, Milan, Italy )
12 Nov 2021
Latest in Philadelphia chromosome-positive ALL (Ph+ ALL)
Prof Robin Foà - Sapienza University of Rome, Rome, Italy
Latest in Philadelphia chromosome-positive ALL (Ph+ ALL) ( Prof Robin Foà - Sapienza University of Rome, Rome, Italy )
11 Nov 2021